Patents Examined by Laura L. Stockton
  • Patent number: 12378243
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Grant
    Filed: February 9, 2024
    Date of Patent: August 5, 2025
    Assignee: Incyte Corporation
    Inventors: Qinda Ye, Matthew McCammant, Rocco Policarpo, Artem Shvartsbart, Wenyu Zhu, Jeremy Roach, Gia Hoang, Bin Hu, Gencheng Li, Robert Susick, Padmaja Polam, Fenglei Zhang, Chao Qi, Xiaozhao Wang, Wenqing Yao, Alexander Sokolsky, Haolin Yin, Le Zhao, Peter Carlsen
  • Patent number: 12378196
    Abstract: The present invention relates to novel methods and compounds for synthesizing amanitin derivatives. The invention in particular relates to methods for synthesizing (S)-6-hydroxy-tryptophan derivatives which can be used as building blocks for synthesizing amanitin derivatives or amatoxin drug conjugates. The invention further relates to intermediate compounds of said synthesis pathways for use in amanitin derivative and amatoxin drug conjugate synthesis, and to the use of particular catalysts suited for mediating said synthesis pathways.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: August 5, 2025
    Assignee: Heidelberg Pharma Research GmbH
    Inventors: Werner Simon, Susanne Werner-Simon, Christoph Müller
  • Patent number: 12351559
    Abstract: Optionally substituted benzoimidazol-1,2-yl amides, such as compounds of Formula 1 or Formula 2, can be used to treat disorders associated with a Kv7 potassium channel activator. Compositions, medicaments, and dosage forms related to the treatment are also disclosed herein.
    Type: Grant
    Filed: October 20, 2023
    Date of Patent: July 8, 2025
    Assignee: Biohaven Therapeutics Ltd.
    Inventors: Lynn Resnick, George T. Topalov, Justin K. Belardi, James S. Hale, Scott S. Harried, Charles A. Flentge, David A. Mareska
  • Patent number: 12351540
    Abstract: This invention relates to a process for producing cyanoacetates using asparagine as a precursor to cyanoacetamide, a staring material to form the cyanoacetates.
    Type: Grant
    Filed: October 18, 2021
    Date of Patent: July 8, 2025
    Assignee: Henkel AG & Co. KGaA
    Inventors: Cormac Duffy, Justine O'Sullivan, Ciara Goff, Umar Farid, Jessica Ramos, Michael Thai Trung King, Isidro Cobo Cardenete, Marisa Phelan, Barry Burns
  • Patent number: 12351541
    Abstract: This invention relates to a process for producing cyanoacetates using a cyanoacetamide as a precursor.
    Type: Grant
    Filed: October 18, 2021
    Date of Patent: July 8, 2025
    Assignee: Henkel AG & Co. KGaA
    Inventors: Cormac Duffy, Justine O'Sullivan, Ciara Goff, Umar Farid, Jessica Ramos, Michael Thai Trung King, Isidro Cobo Cardenete, Marisa Phelan, Barry Burns
  • Patent number: 12351563
    Abstract: A process reduces the odor of compounds with al least one five-membered cyclic monothiocarbonate group, referred to as monothiocarbonate compounds. The monothiocarbonate compounds are in are liquid phase and are brought into contact with an oxidant.
    Type: Grant
    Filed: August 13, 2020
    Date of Patent: July 8, 2025
    Assignee: BASF SE
    Inventors: Indre Thiel, Thomas Maximilian Wurm, Peter Rudolf
  • Patent number: 12338237
    Abstract: Provided are a compound having a 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof, of Formula 1 a pharmaceutical composition comprising the same and a use thereof, where the compound having a 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof has an inhibitory activity against glucosylceramide synthase (GCS), and therefore can be usefully applied for preventing or treating various diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc.
    Type: Grant
    Filed: November 12, 2020
    Date of Patent: June 24, 2025
    Assignees: Yuhan Corporation, Green Cross Corporation
    Inventors: Dong-Hoon Kim, Jae-Eun Joo, Eui-Chul Lee, Tae-Dong Han, Seung-Yub Shin, Sool-Ki Kwon, Young-Gyu Kong, Sang-Ho Ma, Ick-Hwan Son
  • Patent number: 12331020
    Abstract: A method of synthesizing indole compounds. The method may include allyllating an indole compound, oxidizing the resulting ?-indolepropene, and reductively aminating the resulting indoleacetaldehyde, providing a tryptamine. The indole compound may be substituted with a functional group on the indole ring or may be unsubstituted indole. The method may include substitution, oxidation or other derivatization of the indole ring of the indole compound, of tryptophan, of the tryptamine, or of intermediates. The method may include oxidizing tryptophan or a ring-substituted tryptophan analogue and reductively aminating the resulting indoleacetaldehyde, providing a tryptamine. The method may be applied in a telescoped approach without isolation of intermediates. The method may be applied to production of indoles, ?-indolepropenes, indole propyl diols, indoleacetaldehydes and tryptamines. Compounds from each of these classes of compounds are also provided herein.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: June 17, 2025
    Assignee: 1280225 B.C. LTD.
    Inventors: Jason Ellis Hein, Corey Sanz, Shao-Kai Chen, Blessing Cao
  • Patent number: 12319692
    Abstract: The present invention discloses a class of anti-influenza virus compounds, and the use thereof in the preparation of a drug for treating diseases associated with influenza viruses. In particular, the present invention discloses a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 19, 2023
    Date of Patent: June 3, 2025
    Assignee: GUANGDONG RAYNOVENT BIOTECH CO., LTD.
    Inventors: Jian Xiong, Chaofeng Long, Jingjing Wang, Xiaoxin Chen, Kevin X Chen, Cheng Xie, Peng Li, Xuanjia Peng, Jian Li, Shuhui Chen
  • Patent number: 12319652
    Abstract: The present disclosure is directed to salt and solid forms of (R)-1-(5-METHOXY-1H-INDOL-1-YL)-N,N-DIMETHYLPROPAN-2-AMINE and methods of treating neurological disorder and/or a psychiatric disorder in a subject in need thereof.
    Type: Grant
    Filed: March 2, 2023
    Date of Patent: June 3, 2025
    Assignee: Terran Biosciences Inc.
    Inventors: Matthew Duncton, Samuel Clark
  • Patent number: 12291510
    Abstract: The disclosed technology relates to derivatives of 2,5-dimercapto-1,3,4-thiadiazole.
    Type: Grant
    Filed: September 16, 2020
    Date of Patent: May 6, 2025
    Assignee: The Lubrizol Corporation
    Inventors: Paul E. Adams, Christopher M. Rasik, Ryan Richard Konrad
  • Patent number: 12286416
    Abstract: Provided is a process for the preparation of a compound with at least one five-membered cyclic monothiocarbonate group. A compound C1 with at least one halohydrin group is used as starting material. Compound C1 is reacted with phosgene or an alkyl chloroformate to give an adduct C2. The adduct C2 is reacted with a compound that includes anionic sulfur to obtain the compound with at least one five-membered cyclic monothiocarbonate group.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: April 29, 2025
    Assignee: BASF SE
    Inventors: Peter Rudolf, Indre Thiel, Thomas Maximilian Wurm, Joaquim Henrique Teles, Jan-Dirk Arndt
  • Patent number: 12286410
    Abstract: Provided are carbazole-based host compounds containing a 9-membered ring represented by Formula I where the variables are defined herein. Also provided are formulations comprising these carbazole-based hosts compounds. Further provided are OLEDs and related consumer products that utilize these carbazole-based hosts compounds.
    Type: Grant
    Filed: April 14, 2021
    Date of Patent: April 29, 2025
    Assignee: UNIVERSAL DISPLAY CORPORATION
    Inventors: Suman Layek, Hsiao-Fan Chen, Tyler Fleetham
  • Patent number: 12286408
    Abstract: Provided herein are optionally substituted benzoimidazol-1,2-yl amides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating Kv7 associated diseases, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania and tinnitus with such compounds and pharmaceutical compositions.
    Type: Grant
    Filed: June 20, 2023
    Date of Patent: April 29, 2025
    Assignee: Biohaven Therapeutics Ltd.
    Inventors: Michael E. Bozik, Scott S. Harried, Lynn Resnick, George T. Topalov, Justin K. Belardi, Charles A. Flentge, David A. Mareska, James S. Hale
  • Patent number: 12281083
    Abstract: Provided herein are therapeutic and/or prophylactic compounds for mitochondrial or oxidative stress diseases such as cancer, amyotropic lateral sclerosis, Creutzfeldt-Jakob disease, Machado-Joseph disease, spinocerebellar ataxia, Huntington disease, Parkinson disease, Alzheimer disease, myocardial infarction, cerebral infarction, diseases related to aging, diabetes, alcoholic liver injury, chronic obstructive pulmonary disease, mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS), and the like, wherein the compound is represented by formula (1), or reduced forms thereof, or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: July 11, 2022
    Date of Patent: April 22, 2025
    Assignee: PTC Therapeutics, Inc.
    Inventors: Hiroyuki Kitano, Kazuto Mori
  • Patent number: 12275721
    Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: April 15, 2025
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jie Chen, Carolyn Diane Dzierba, Junqing Guo, Amy C. Hart, William J. Pitts, Sing-Yuen Sit
  • Patent number: 12269808
    Abstract: An amino dithioperacid thioester compound, a preparation method therefor, and use thereof. The structural formula of compound is as shown in formula I: wherein m=1-11, X is a nitrogen-containing aliphatic heterocyclic ring, and a nitrogen atom in the aliphatic heterocyclic ring is connected to a carbon atom of a thiocarbonyl group. The compounds disclosed by the invention are found to be capable of relieving muscular atrophy and lipolysis caused by cancer cachexia through in-vivo and in-vitro experiments. The compounds are also capable of obviously relieving weight and food intake reduction caused by cancer cachexia in animal experiments, so that the carbamo(dithioperoxo)thioates compounds have the effect on resisting cancer cachexia, can be applied to the treatment of cancer cachexia and related diseases, and become one kind of ideal cancer cachexia treatment medicament.
    Type: Grant
    Filed: November 27, 2020
    Date of Patent: April 8, 2025
    Assignees: FUDAN UNIVERSITY, EAST CHINA NORMAL UNIVERSITY
    Inventors: Weili Zhao, Xiongwen Zhang, Xiaochun Dong, Yiwei Li, Shuang Xu, Shanshan Lu, Guangyu Lin, Kedan Gu
  • Patent number: 12264158
    Abstract: The invention relates to pyrazolo-pyridine compounds which inhibit mitogen-activated protein kinase kinase 4 (MKK4) and in particular, selectively inhibit MKK4 over protein kinases JNK1 and MKK7. The compounds are useful for promoting liver regeneration or reducing or preventing hepatocyte death. They are further useful for treating osteoarthritis or rheumatoid arthritis, or CNS-related diseases.
    Type: Grant
    Filed: November 8, 2023
    Date of Patent: April 1, 2025
    Assignee: HEPAREGENIX GMBH
    Inventors: Bent Praefke, Philip Klövekorn, Roland Selig, Wolfgang Albrecht, Stefan Laufer
  • Patent number: 12264173
    Abstract: The present disclosure provides compounds for treating a variety of diseases, such as respiratory syncytial virus (RSV), HRV, hMPV, Ebola, Zika, West Nile, Dengue, and HCV.
    Type: Grant
    Filed: July 18, 2023
    Date of Patent: April 1, 2025
    Assignee: Gilead Sciences, Inc.
    Inventors: Gregory F. Chin, Byoung-Kwon Chun, Michael O. Clarke, Bindu Goyal, Hon C. Hui, Petr Jansa, Richard L. Mackman, Dustin S. Siegel, Hai Yang
  • Patent number: 12258366
    Abstract: The present disclosure is directed to modulators of SOS1 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: October 11, 2022
    Date of Patent: March 25, 2025
    Assignee: Revolution Medicines, Inc.
    Inventors: Adrian L. Gill, Andreas Buckl, Elena S. Koltun, Naing Aay, Arlyn A. Tambo-ong, Severin Thompson, Micah James Gliedt, John E. Knox, James Cregg, Anne V. Edwards, Yang Liu, G. Leslie Burnett